Advertisement

Pain Management for Chronic Abdominal Pain

  • Enas KandilEmail author
Chapter
  • 88 Downloads

Abstract

Chronic abdominal pain is a complex medical problem and is the leading symptom for referral to a gastroenterologist [1]. Causes of chronic abdominal pain are diverse and can require an extensive workup and repeated imaging sometimes with no clear etiology [2, 3]. Abdominal pain may be due to somatic reasons transmitted through A-delta nociceptors as in chronic abdominal wall pain (CAWP) or visceral reasons transmitted through C-type nociceptors as in chronic pancreatitis and ulcerative colitis. A detailed history and physical examination are key in addressing abdominal pain. Attention to the patient’s pain symptomatology details may reveal the etiology and assist in decision for the best management approach.

Keywords

Abdominal pain Visceral pain Somatic pain Celiac block Hypogastric plexus block Ganglion impar block 

References

  1. 1.
    Peery AF, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–1187 e3.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Pichetshote N, Pimentel M. An approach to the patient with chronic undiagnosed abdominal pain. Am J Gastroenterol. 2019;114(5):726–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Glissen Brown JR, et al. Chronic abdominal wall pain: an under-recognized diagnosis leading to unnecessary testing. J Clin Gastroenterol. 2016;50(10):828–35.PubMedCrossRefGoogle Scholar
  4. 4.
    van Assen T, et al. Chronic abdominal wall pain misdiagnosed as functional abdominal pain. J Am Board Fam Med. 2013;26(6):738–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Bharucha AE, Chakraborty S, Sletten CD. Common functional gastroenterological disorders associated with abdominal pain. Mayo Clin Proc. 2016;91(8):1118–32.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Costanza CD, Longstreth GF, Liu AL. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol. 2004;2(5):395–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Oor JE, Unlu C, Hazebroek EJ. A systematic review of the treatment for abdominal cutaneous nerve entrapment syndrome. Am J Surg. 2016;212(1):165–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Ray BS, Neill CL. Abdominal visceral sensation in man. Ann Surg. 1947;126(5):709–24.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–63.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Keefer L, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016;150(6)1408–19.CrossRefGoogle Scholar
  11. 11.
    Kefalakes H, et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65(10):963–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology. 1989;96(2 Pt 2 Suppl):596–605.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonner GF, et al. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95(8):1946–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Mahadevan U, et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97(4):910–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Stenson WF. Safety of selective cyclooxygenase-2-inhibitors in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8(6):429–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Sandborn WJ, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4(2):203–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenblum A, et al. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Chou R, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):147–59.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang D. Opioid medications in the management of chronic abdominal pain. Curr Pain Headache Rep. 2017;21(9):40.PubMedCrossRefGoogle Scholar
  20. 20.
    Lichtenstein GR, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Sullivan MD, et al. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010;149(2):345–53.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Manchikanti L, Boswell MV, Singh V. Monitoring of patients receiving long-term opioid therapy. Anesth Analg. 2004;99(1):304; author reply 304–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med. 2018;69:451–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Jackson JL, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108(1):65–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1(3):219–28.PubMedCrossRefGoogle Scholar
  26. 26.
    Ford AC, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367–78.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Tabas G, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99(5):914–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Kane S, Altschuler EL, Kast RE. Crohn’s disease remission on bupropion. Gastroenterology. 2003;125(4):1290.PubMedCrossRefGoogle Scholar
  29. 29.
    Kast RE, Altschuler EL. Remission of Crohn’s disease on bupropion. Gastroenterology. 2001;121(5):1260–1.PubMedCrossRefGoogle Scholar
  30. 30.
    Mikocka-Walus AA, et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2:24.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(10):981–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Houghton LA, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218–25.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Camilleri M, Oduyebo I, Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):G777–84.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Keefer L, Mandal S. The potential role of behavioral therapies in the management of centrally mediated abdominal pain. Neurogastroenterol Motil. 2015;27(3):313–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Creed F, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124(2):303–17.PubMedCrossRefGoogle Scholar
  37. 37.
    Weibert E, Stengel A. The role of psychotherapy in the treatment of irritable bowel syndrome. Psychother Psychosom Med Psychol. 2019;69:360–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Mohamadi J, Ghazanfari F, Drikvand FM. Comparison of the effect of dialectical behavior therapy, mindfulness based cognitive therapy and positive psychotherapy on perceived stress and quality of life in patients with irritable bowel syndrome: a pilot randomized controlled trial. Psychiatry Q. 2019;90:565–78.CrossRefGoogle Scholar
  39. 39.
    Li L, et al. Cognitive-behavioral therapy for irritable bowel syndrome: a meta-analysis. J Psychosom Res. 2014;77(1):1–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Tang QL, Lin GY, Zhang MQ. Cognitive-behavioral therapy for the management of irritable bowel syndrome. World J Gastroenterol. 2013;19(46):8605–10.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Gunduz OH, Kenis-Coskun O. Ganglion blocks as a treatment of pain: current perspectives. J Pain Res. 2017;10:2815–26.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Rathmell JP, Gallant JM, Brown DL. Computed tomography and the anatomy of celiac plexus block. Reg Anesth Pain Med. 2000;25(4):411–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhong W, et al. Celiac plexus block for treatment of pain associated with pancreatic cancer: a meta-analysis. Pain Pract. 2014;14(1):43–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Kawamata M, et al. Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain. 1996;64(3):597–602.PubMedCrossRefGoogle Scholar
  45. 45.
    Zhang CL, et al. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci. 2008;53(3):856–60.PubMedCrossRefGoogle Scholar
  46. 46.
    Stefaniak T, et al. A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy. Eur J Surg Oncol. 2005;31(7):768–73.PubMedCrossRefGoogle Scholar
  47. 47.
    Jain PN, et al. Neurolytic celiac plexus block: a better alternative to opioid treatment in upper abdominal malignancies: an Indian experience. J Pain Palliat Care Pharmacother. 2005;19(3):15–20.PubMedGoogle Scholar
  48. 48.
    Fujii L, et al. Anterior spinal cord infarction with permanent paralysis following endoscopic ultrasound celiac plexus neurolysis. Endoscopy. 2012;44(Suppl 2 UCTN):E265–6.PubMedGoogle Scholar
  49. 49.
    Kambadakone A, et al. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics. 2011;31(6):1599–621.PubMedCrossRefGoogle Scholar
  50. 50.
    Mishra S, et al. Efficacy of the anterior ultrasound-guided superior hypogastric plexus neurolysis in pelvic cancer pain in advanced gynecological cancer patients. Pain Med. 2013;14(6):837–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Kanazi GE, et al. New technique for superior hypogastric plexus block. Reg Anesth Pain Med. 1999;24(5):473–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Wemm K Jr, Saberski L. Modified approach to block the ganglion impar (ganglion of Walther). Reg Anesth. 1995;20(6):544–5.PubMedGoogle Scholar
  53. 53.
    Eker HE, et al. Transsacrococcygeal approach to ganglion impar for pelvic cancer pain: a report of 3 cases. Reg Anesth Pain Med. 2008;33(4):381–2.PubMedGoogle Scholar
  54. 54.
    Lu Y, Bousvaros A. Healthcare burden of inflammatory bowel disease in the United States: more than pain and diarrhea. Inflamm Bowel Dis. 2009;15(11):1767–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(5):778–88.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of Texas SouthwesternDallasUSA

Personalised recommendations